Business Wire

CA-LASERFICHE

28.11.2023 16:01:35 CET | Business Wire | Press release

Share
Healthcare Leaders Cite Automation, Worker Burnout as Top Drivers of Technology Integrations, MGMA and Laserfiche Study Finds

New research by Medical Group Management Association (MGMA) and Laserfiche — the leading SaaS provider of intelligent content management and business process automation — reveals that most healthcare organizations’ top priorities when considering integrative technologies are the elimination of manual work, mitigation of clinician/worker burnout and time savings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128977000/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Discover the opportunities and challenges for medical practice leaders in evaluating their platforms for workflow, electronic forms, document and records management and more. (Graphic: Business Wire)

“The healthcare industry has been disrupted by the growth of virtual visits, expectations for more personal, faster access to patients’ clinical results and care, plus the rise of AI,” said Grace Nam, strategic solutions manager, healthcare, at Laserfiche. “These trends have created a burgeoning challenge of managing, processing and leveraging an inundation of data that require cross-functional collaboration, and often include external organizations like labs and other physicians.”

The study surveyed medical practice administrators, physicians, billing and coding leaders and health information technology (HIT) workers for their views on electronic health records (EHR) or practice management (PM) systems, business automation and more. According to the report, most healthcare organizations are not looking to make a switch to a new EHR or PM system and nearly 80% of respondents rated their current EHR system as “very good” or “good.” However, when it came time to rate EHR systems’ individual attributes, those ratings dropped. Only half of respondents rated their EHR systems “very good” or “good” at saving time; 47% said they were very good or good at saving money; and only 40% said they were very good or good at mitigating clinician/worker burnout.

“Time-strapped organizations need integrated technologies to extract value from data without adding to the long list of manual tasks for already overwhelmed employees,” Nam added. “Investments in systems that enable business process automation while facilitating information governance are critical to healthcare organizations’ ability to leverage data and retain employees while providing a modern patient experience. Supporting the back office — including medical billing and coding, and working with third-party insurance companies — to boost speed and accuracy will be critical for on-time payments that impact revenue.”

“The business of healthcare and its future are tied directly to the ability to manage and make decisions based on data to support high-quality patient care,” the report states. “As the amount of data generated in healthcare grows about 47% a year, the need to manage the growing volumes of records in a secure, compliant fashion is unmistakable.”

To download a copy of the Intelligent Automation in Healthcare report, visit https://info.laserfiche.com/resource/intelligent-automation-healthcare.

To learn more about Laserfiche solutions for the healthcare industry, visit laserfiche.com/solutions/healthcare.

About Laserfiche

Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through workflows, e-forms, document management, integrations and analytics, the Laserfiche® platform centralizes information, structures clinical data and streamlines back-office processes so that healthcare professionals can focus on providing the highest standard of patient care.

For over 30 years, Laserfiche has served organizations in the healthcare industry as a trusted system for document and records management, enabling medical professionals to quickly retrieve records when needed, with robust security and compliance tools to support HIPAA compliance and patient confidentiality. By streamlining paperwork, information and data using digital forms and automated workflows, Laserfiche allows administration, clinicians and physicians to eliminate repetitive manual tasks, gain visibility into operations, support a holistic approach to patient care and focus on improving patient outcomes. Prebuilt solutions and integrations with industry-specific and common business applications further extend organizations’ digital transformation initiatives.

Today, Laserfiche’s cloud-first approach incorporates innovations in machine learning and AI, supporting healthcare organizations in empowering staff, streamlining the patient experience, supporting HIPAA compliance and providing the best possible patient experience.

Learn more at laserfiche.com/solutions/healthcare.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231128977000/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye